- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04449510
Short-Term Cardiovascular Effects of E-Cigarettes: Influence of E-Liquid pH (TCORS-2)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single-site, randomized, crossover study of experienced adult e-cigarette users to assess nicotine exposure, toxicant exposure, and the short-term CV effects of e-liquid pH. Three e-liquid pH conditions will be assessed on all participants: 5, 7, and 9.
Hypothesis 2a: The rate of systemic nicotine absorption is inversely related to e-liquid pH and results in lower peak blood nicotine levels at higher pH.
Hypothesis 2b: Heart rate acceleration will decrease and subjective measures of sensation in the throat, reward, and satisfaction will increase with increasing e-liquid pH.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Lisa Lawrence
- Phone Number: (415) 608-4864
- Email: Lisa.Lawrence@ucsf.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- Recruiting
- University of California, San Francisco
-
Contact:
- Lisa Lawrence
- Email: Lisa.Lawrence@ucsf.edu
-
Principal Investigator:
- Gideon St. Helen, PhD
-
San Francisco, California, United States, 94110
- Recruiting
- Zuckerberg San Francisco General Hospital
-
Contact:
- Lisa Lawrence
- Email: Lisa.Lawrence@ucsf.edu
-
Principal Investigator:
- Gideon St. Helen, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Heart rate < 105 beats per minute (BPM)*
- Systolic Blood pressure <160 and > 90*
- Diastolic Blood Pressure <100 and > 50*
Body Mass Index (BMI) < 38.0 (at investigator's discretion for higher BMI if no other concurrent health issues)
*considered out of range if both machine and manual readings are above/below these thresholds
- Use e-cigarettes on at least 15 days in the past 30 for at least 3 months
- Smoke 10 or fewer cigarettes/tobacco products per day in the last 30 days
- Willing to use mod e-cigarette
- Willing to abstain from tobacco product use for night before study
- Age: > 21 years old and < 70 years old
- Using e-liquid > 0mg/ml nicotine
- Saliva cotinine of ≥ 30 ng/ml or NicAlert=6 (in cases where lab turn around time will delay study procedure)
Exclusion Criteria:
- Seizures
- Cancer
- Hepatitis B or C or Liver Disease
- Oral Thrush
- Heart disease
- Glaucoma
- Kidney disease or urinary retention
- Diabetes
- High Blood Pressure (taking sympatholytic medications such as alpha and beta blockers)
- History of stroke
- An ulcer in the past year
- Thyroid disease (okay if controlled with medication)
- Active use of an inhaler for asthma or Chronic Obstructive Pulmonary Disease (COPD)
- Psychiatric conditions
- Current or past schizophrenia, and/or current or past bipolar disorder
- Major depression, current or within the past year
- Major personality disorder
- Participants with current or past minor or moderate depression and/or anxiety disorders will be reviewed by the study physician and considered for inclusion.
- History of psychiatric hospitalizations are not exclusionary, but study participation will be determined as per study physician's approval
- Recent onset or change in cough, fever and/or abdominal symptoms (vomiting or pain) in the past two weeks. (If yes, participant can re-screen when symptoms resolve).
- Drug/Alcohol Dependence
- Alcohol or illicit drug dependence within the past 12 months with the exception of those who have recently completed an alcohol/drug treatment program
- Positive toxicology test at the screening visit (THC & prescribed medications okay)
- Opioid replacement therapy (including methadone, buprenorphine, or other)
- Positive urine cannabis is not exclusionary but participant must report use of cannabis and agree to abstain from cannabis use for the duration of the study
- Psychiatric medications
- Current regular use of any psychiatric medications with the exception of Selective Serotonin Reuptake Inhibitor (SSRI) and serotonin-norepinephrine reuptake Inhibitor (SNRIs) and current evaluation by the study physician that the participant is otherwise healthy, stable, and able to participate.
- Medications
- Use of medications that are inducers of nicotine metabolizing enzyme CYP2A4 (Example: rifampicin, carbamazepine, phenobarbital, and other anticonvulsant drugs).
- Concurrent use of nicotine-containing medications
- Any stimulant medications (example: Adderall) generally given for Attention deficit hyperactivity disorder (ADHD) treatment
- Use of sympatholytic medications that affect cardiovascular conditions including hypertension, (Example: beta and alpha-blockers)
- Other/Misc. Chronic Health Conditions
- Fainting (within the last 30 days)
- Other "life threatening illnesses" as per study physician's discretion
- Pregnancy
- Pregnancy (self-reported and urine pregnancy test)
- Breastfeeding (determined by self-report)
- Concurrent participation in another clinical trial
- Inability to communicate in English
- Planning to quit vaping within the next 60 days
- Uncomfortable with getting blood drawn
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: E-liquid pH 5, 7, or 9
Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of 3 assigned e-liquid pH.
|
E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W. The device will be set at 10 watts for the study visits.
|
Other: 1 of the other 2 remaining e-liquid pH
Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of the other 2 assigned e-liquid pH.
|
E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W. The device will be set at 10 watts for the study visits.
|
Other: Remaining e-liquid pH
Using an electronic cigarette, the patient will participate in a standardized vaping session using the remaining assigned e-liquid pH.
|
E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W. The device will be set at 10 watts for the study visits.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nicotine Exposure: Blood Nicotine
Time Frame: Day 1 of each Arm
|
Concentration of plasma nicotine (ng/ml) will be used to assess differences across the three e-liquid pH levels.
|
Day 1 of each Arm
|
Nicotine Exposure: Saliva pH
Time Frame: Day 1 of each Arm
|
Participant saliva pH will be measured before and during outpatient stay.
|
Day 1 of each Arm
|
Subjective Effects: Withdrawal
Time Frame: Day 1 of each Arm
|
We will compile a score for the subjective effect of withdrawal using the sum of points scored on the Minnesota Nicotine Withdrawal Scale (MNWS), where a higher score (score range from 0 points to 60 points) indicates a higher intensity of the indicated subjective effect.
|
Day 1 of each Arm
|
Subjective Effects: Craving
Time Frame: Day 1 of each Arm
|
We will compile a score for the subjective effect of craving using the sum of points scored in the two subscales (intention and desire to engage in smoking behavior that is anticipated as pleasant, and anticipation of relief from negative affect through smoking) of the Questionnaire of Smoking Urges (QSU-Brief), where a higher score (score range from 10 points to 70 points) indicates a higher intensity of the indicated subjective effect.
|
Day 1 of each Arm
|
Subjective Effects: Reward
Time Frame: Day 1 of each Arm
|
We will compile a score for the subjective effect of reward using the sum of points scored in the five subscales (Smoking Satisfaction - score range from 1 point to 7 points; Psychological Reward - score range from 5 points to 35 points; Aversion - score range from 2 points to 14 points; Enjoyment of Respiratory Tract Sensations - score range from 2 points to 14 points; and Craving Reduction - score range from 1 point to 7 points) of the modified Cigarette Evaluation Scale (mCES), where a higher score indicates a higher intensity of the indicated subjective effect.
|
Day 1 of each Arm
|
Cardiovascular Effects: Heart Rate
Time Frame: Day 1 of each Arm
|
Participant heart rate will be measured in beats per minute throughout the outpatient stay.
|
Day 1 of each Arm
|
Cardiovascular Effects: Skin Blood Flow
Time Frame: Day 1 of each Arm
|
Participant skin blood flow will be measured by product of average blood cell velocity and concentration in mL/min during outpatient stay.
|
Day 1 of each Arm
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vaping Topography: Puff Number
Time Frame: Day 1 of each Arm
|
Vaping topography measures will be obtained from frame by frame analysis of high definition videos during the ad libitum sessions and measured as puffs per minute.
|
Day 1 of each Arm
|
Vaping Topography: Puff Duration
Time Frame: Day 1 of each Arm
|
Vaping topography measures will be obtained from frame by frame analysis of high definition videos during the ad libitum sessions and measured as seconds per puff.
|
Day 1 of each Arm
|
Vaping Topography: Inter-Puff Interval
Time Frame: Day 1 of each Arm
|
Vaping topography measures will be obtained from frame by frame analysis of high definition videos during the ad libitum sessions and measured as seconds/minutes between puffs.
|
Day 1 of each Arm
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Gideon St. Helen, PhD, University of California, San Francisco
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-30597
- 2U54CA180890-06 (U.S. NIH Grant/Contract)
- U54HL147127 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Risk Factor
-
University of Southern DenmarkRegion of Southern Denmark; Odense Patient Data Explorative Network; ENIGMA Solutions... and other collaboratorsActive, not recruitingCardiovascular Risk Factor | Risk CommunicationDenmark
-
University of Split, School of MedicineCompletedCardiovascular Risk Factor | Lifestyle Risk ReductionCroatia
-
University of DelawareRecruiting
-
University Health Network, TorontoSunnybrook Health Sciences Centre; MOUNT SINAI HOSPITALRecruitingCardiovascular Risk FactorCanada
-
University of DelawareRecruitingCardiovascular Risk FactorUnited States
-
The Cleveland ClinicActive, not recruitingCardiovascular Risk FactorUnited States
-
University of NebraskaCompletedCardiovascular Risk FactorUnited States
-
Oregon Health and Science UniversityCompleted
-
Dawn BrewerNational Institute of Environmental Health Sciences (NIEHS)Completed
-
Penn State UniversityActive, not recruitingCardiovascular Risk FactorUnited States
Clinical Trials on Electronic Cigarette
-
Virginia Commonwealth UniversityCompletedElectronic CigarettesUnited States
-
Massachusetts General HospitalWithdrawn
-
University of California, San FranciscoNational Cancer Institute (NCI); National Institutes of Health (NIH); Food and...CompletedCardiovascular Risk Factor | Nicotine DependenceUnited States
-
Karolinska InstitutetCompleted
-
GWT-TUD GmbHTerminated
-
University of PennsylvaniaNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedEndothelial Dysfunction | Biochemical MarkersUnited States
-
University of California, San FranciscoNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH); Roswell Park Cancer InstituteCompleted
-
Queen's University, BelfastUnknownAcute Lung InjuryUnited Kingdom
-
University of AthensUnknown
-
Miami VA Healthcare SystemUnknownSmoking Cessation | Airway Morbidity | Smoking, Tobacco | Smoking, Cigarette | Nicotine Adverse ReactionUnited States